References
- Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434–40.
- Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79: 320–7.
- Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol 2001; 22: 217–20.
- Sardi J, Anchezar Henry JP, Paniceres G, Gomez Rueda N, Vighi S. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Oncol 1998; 19: 565–8.
- Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001; 167: 39–48.
- Vinker S, Shani A, Open M, Fenig E, Dgani R. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate? Eur J Obstet Gynecol 1999; 83: 63–5.
- Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995; 52: 269–76.
- Silverberg SG, Haukkamaa M, Nilsson CG, Luukkainen T. Endometrial morphology during longterm use of levonorgestrel-releasing intrauterine device. Int J Gynecol Pathol 1986; 5: 235–41.
- Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74–86.
- Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta CA. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception 2002; 65: 325–8.
- Nilsson CG, Haukkamaa M, Viertola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel IUD. Clin Endocrinol 1982; 17: 529–36.
- Nilsson CG, Läteenmaki P, Robertson DN, Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol 1980; 93: 380–4.
- Nilsson CG, Lahteenmaki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980; 21: 225–33.
- Pakarinen P, Luukkainen T, Laine H, Läteenmäki P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Hum Reprod 1995; 10: 2390–4.
- Jarvela I, Tekay A, Jouppila P. The effect of a levonorges- trel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998; 13: 3379–83.
- Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy. Menopause 2001; 8: 420–3.